Predictive value of Serum S-100B protein in predicting relapse in patients with melanoma

Abstract

7532 Background: S-100B protein is correlated with clinical stage in patients (p.) with melanoma. A few studies have been reported a significant correlation with progression of disease in p. receiving antitumoral treatment. We investigated the value of S-100B a predictor of relapse and survival in p. during follow-up. Methods: From January.02 to October.03 273 peripheral blood samples were obtained from 110 p. diagnosed with melanoma. Serum concentrations of S-100B protein were measured by ELISA. Normal range of S-100B was 0 to 0,150 micrograms/L. Median age was 49.5 years (range 4 - 81), with 55 males and 55 females. 39 (35.5 %) p. were stage I, 21 p. (19.1 %) stage II, 31 p. (28.2 %) stage III and 19 p. (17.3 %) stage IV. Results: Median number of determinations of S-100B was: 2.48 (range:1–5). Median follow-up was 555 days. The frequency of relapse in p with S-100 <0.150 micrograms/L was 8.33 % versus 25.93 % in p with S-100>0.150 in a single determination, and 52.17 % in p with S-100>0.150 in two or more determinations. Stage was an independent factor of progression (p<0.05) but S100B protein was not borderline statistically significant (p= 0.0557)in a multivariate analysis (Cox regression). Conclusions: Level of serum S100B protein is a predictor factor of progression or relapse in melanoma, although should be confirm with more studies. No significant financial relationships to disclose.